Table 1.

Baseline characteristics of included articles.

Author	Year	Country	Type	GC	MVAC	PCR	PPR	OS
Roberts (8)	2006	The USA	RCT	164	151	Y	N	Y
				NA	NA
Dash (9)	2008	The USA	RCS	42	54	Y	Y	N
				4 cycle	4 cycle
Weight (10)	2009	The USA	RCS	23	4	Y	N	N
				3 cycle	4 cycle
Kaneko (11)	2011	Japan	RCS	22	9	Y	Y	N
				NA	NA
Pal (12)	2012	The USA	RCS	24	22	Y	Y	N
				3-4 cycle	3-4 cycle
Yeshchina (13)	2012	Japan	RCS	16	45	Y	Y	Y
				NA	NA
Fairey (14)	2013	The USA	RCS	58	58	Y	Y	Y
				4 cycle	4 cycle
Iwasaki (15)	2013	Japan	RCS	34	34	Y	N	N
				2-3 cycle	2-3 cycle
Lee (16)	2013	The USA	RCS	41	31	Y	Y	N
				NA	NA
Meijer (17)	2013	Netherland	RCS	45	117	Y	N	N
				2-4 cycle	2-4 cycle
Zargar (18)	2015	The USA	RCS	602	183	Y	N	N
				3-4 cycle	3-4 cycle
Galsky (19)	2015	The USA	RCS	146	66	Y	N	Y
				3-4 cycle	3-4 cycle
Putte (20)	2016	The USA	RCS	115	51	Y	N	N
				4 cycle	4 cycle
Nguyen (21)	2018	The USA	RCT	23	4	Y	Y	N
				3 cycle	3 cycle
Peyton (22)	2018	The USA	RCS	204	46	Y	Y	Y
				3-4 cycle	3-4 cycle
Pfister (23)	2021	France	RCT	198	199	Y	Y	N
				4 cycle	6 cycle
Ruplin (24)	2020	The USA	RCS	76	33	Y	Y	N
				3-4 cycle	3-4 cycle
Flaig (25)	2021	The USA	RCT	82	85	Y	Y	N
				4 cycle	4 cycle

GC, Gemcitabine plus Cisplatin; MVAC, Methotrexate, vinblastine, doxorubicin, and cisplatin; PCR, Pathological Complete Response; PPR, Pathological Partial Response; OS, Overall Survival; RCT, Randomized controlled Trial; RCS, Retrospective Study; Y, Yes; N, No; NA, Not Available.